Project Grant R21AI193960
Award Date
7/22/25
Completion Date
6/30/27
Dollars Obligated
$159K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11794, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat gastrointestinal acute radiation syndrome (GI-ARS) in individuals exposed to high doses of ionizing radiation. The $167,500 award to The Feinstein Institutes for Medical Research, a non-profit medical research organization, will fund research to determine the mechanism of...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is for the development of a thrombopoietin mimetic (TPOM) as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The total award amount is $593,823 with a project period from December 2024 to November 2029. The primary awardee, Albert Einstein College of Medicine, is collaborating with The Henry M. Jackson Foundation for the...
This U01 Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the mechanism by which the hormone ghrelin confers radioprotection to the gastrointestinal (GI) system and to preclinically develop human ghrelin as a safe and effective mitigator for GI acute radiation syndrome (GI-ARS). The total funding amount is $586,240 over the period of December 5, 2024 to November 30, 2029. The research will be...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $552,787.00 to Old Dominion University and its affiliated research foundation (ODURF) to develop YK-4-250, a novel radiation mitigator targeting the renin-angiotensin system and reactive oxygen species signaling to treat gastrointestinal acute radiation syndrome (GI-ARS). The research aims to investigate the mechanisms underlying GI-ARS, assess...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $157,500.00 to the University of California, Los Angeles (UCLA) to develop and test new radiation mitigator compounds based on the estrogen receptor beta (ER-beta) agonist DPN. The goal is to create orally bioavailable DPN analogues that can more effectively treat bone marrow, gastrointestinal, respiratory, and cardiovascular injuries caused by total-body...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) seeks to develop novel mitigators of gastrointestinal acute radiation syndrome (GI-ARS) by targeting the STING-clusterin (CLU) axis to promote regeneration of irradiated intestinal epithelium. The total award amount is $515,326, with a project period from December 2, 2024 to November 30, 2029. Key objectives include defining the mechanisms by which CLU...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $470,309.00 to Chromologic LLC, a minority-owned small business in Monrovia, CA, to develop a genetically modified probiotic for mitigating radiation-induced gastrointestinal and hematopoietic injuries. The project aims to engineer a second-generation probiotic that can deliver a known mitigator, interferon-beta, to the gastrointestinal tract to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...
This Cooperative Agreement award, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to develop a novel radiation biodosimetry tool based on autofluorescence imaging. The University of California, Los Angeles (UCLA) will receive $551,250 over the period of July 2025 to May 2030 to conduct this research. The key objectives are to: Determine the dose-response and time course of radiation-induced autofluorescence in vitro, which will...
The U.S. Defense Health Agency awarded a $624,000 Project Grant to Georgetown University under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING OVARIAN STROMAL CELL SENESCENCE TO MITIGATE IR-INDUCED TRANSGENERATIONAL GASTROINTESTINAL CANCER RISK." The grant, with a performance period from July 1, 2024 to June 30, 2026, will support Georgetown's scientific investigation into developing treatments to address the increased risk of...